Table 1.
Characteristics of the patients, tumors and treatments
| Variables | No. of patients (total:10) | % |
|---|---|---|
| Age (years) | ||
| Median | 73 | |
| Range | 50–85 | |
|
| ||
| Histopathological subtype | ||
| Adenocarcinoma | 8 | 80 |
| Small cell carcinoma | 2 | 20 |
|
| ||
| Initial T-stage | ||
| T1–2 | 3 | 30 |
| T3–4 | 7 | 70 |
|
| ||
| Initial N-stage | ||
| N0 | 3 | 30 |
| N1 | 7 | 70 |
|
| ||
| Initial M-stage | ||
| M0 | 4 | 40 |
| M1 | 6 | 70 |
|
| ||
| PSA (ng/mL) | ||
| Mean | 49.40 | |
| Range | 3–100 | |
|
| ||
| Gleason score | ||
| ≥7 | 10 | 100 |
| ≥8 | 8 | 80 |
|
| ||
| Curative prostate surgery | ||
| Yes | 4 | 40 |
| No | 6 | 60 |
|
| ||
| Postoperative prostate radiotherapy | ||
| Yes | 2 | 20 |
| No | 8 | 80 |
|
| ||
| Brain irradiation dose | ||
| 30 Gy | 5 | 50 |
PSA: prostate-specific antigen